Navigation Links
Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
Date:4/2/2009

cations/anti-aging.php" target="_new">rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.

For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the Company's expectations, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which are filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as o
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cynosure Receives CE Mark for Smartlipo MPX(TM) Workstation
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... -- Robbins & Myers, Inc. (NYSE: RBN ... its fiscal 2010 first quarter ending November 30, 2009, ... A live webcast is scheduled for ... Peter C. Wallace, President and Chief Executive Officer, ... Officer, will be discussing the Company,s performance and responding ...
(Date:12/15/2009)... LOUIS, Dec. 15 KV Pharmaceutical ... 2009, the Company received a written notice (the "Notice") ... 7/23/99, a stockholder of the Company, requesting that the ... a record date for stockholder action by written consent ... fill a vacant director seat resulting from Ronald J. ...
(Date:12/15/2009)... Dec. 15 SRI International, an independent ... award of U.S. patent 7,592,021 for a new ... of drugs through the human body,s mucous membranes. ... and allows for a much longer release time ... ,, Transmucosal delivery is an effective means to ...
Breaking Medicine Technology:KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 2KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 3KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 4KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 5KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 6KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 7SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 2SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 3SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 4SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 5Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 14449 1Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 14449 2Resverlogix Appoints A Brad Cann as Chief Financial Officer 14444 1Resverlogix Appoints A Brad Cann as Chief Financial Officer 14444 2Resverlogix Appoints A Brad Cann as Chief Financial Officer 14444 3MicroRNA Biomarkers Provide Reliable Diagnosis from Blood Samples 5428 1MicroRNA Biomarkers Provide Reliable Diagnosis from Blood Samples 5428 2
... 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, ... studies that,support the role of SPARC (secreted ... cancer and Abraxis' nanoparticle,albumin-bound (nab(TM)) tumor-targeting technology ... (AACR) Annual Meeting held,April 14-18, 2007 in ...
... Md., April 19, 2007 /PRNewswire-FirstCall/--,EntreMed, Inc. , ... treatment of cancer and inflammatory diseases,today announced ... novel cell cycle inhibitor. The data were ... for Cancer Research (AACR),Annual Meeting being held ...
Other Medicine Technology:Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 2Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 3Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 4Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 5EntreMed Presents Preclinical Data for MKC-1 in Hematological,Cancers 2EntreMed Presents Preclinical Data for MKC-1 in Hematological,Cancers 3EntreMed Presents Preclinical Data for MKC-1 in Hematological,Cancers 4
(Date:12/15/2009)... Food and Health Bureau has invited expressions of interest ... private hospitals at four sites in the Hong Kong ... March 31, 2010. ,, At a press conference, ... said the promotion of private hospital development was one ... Hong Kong government policy announced by Chief Executive Donald ...
(Date:12/15/2009)... Dec. 15 Our Lady of Lourdes Health ... Jersey hospitals, has agreed to pay the United States ... Medicare, the Justice Department announced today. The two hospitals ... Camden, N.J., and Lourdes Medical Center of Burlington County ... defendant in a suit brought by a whistleblower, Tony ...
(Date:12/15/2009)... would have really been in trouble, expert says , , ... the pandemic H1N1 swine flu has revealed serious flaws ... emergencies, a new report says. , The report, prepared ... Wood Johnson Foundation, also finds the dire economy has ... 2009 H1N1 outbreak is the latest in a series ...
(Date:12/15/2009)... will train advocates to be leaders in the ... with support from experts in online learning, the ... Dec. 15 ONE and ... applications for the first-ever "Malaria Griots" program, a ... participants to become leaders in the fight against ...
(Date:12/15/2009)... Patient advocate Betsy McCaughey, Ph.D., ... that, "it doesn,t matter whether there,s a public option. ... public option - give government authority over how your ... new social agenda by shifting billions of dollars from ... immigrants, and local politicians." ,, Betsy McCaughey ...
Breaking Medicine News(10 mins):Health News:Hong Kong Government Invites Expressions of Interest in Development of Private Hospitals 2Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2Health News:Serious Gaps Revealed in U.S. Response to Health Emergencies 2Health News:Serious Gaps Revealed in U.S. Response to Health Emergencies 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 2Health News:ONE and Malaria No More Launch 'Malaria Griots' 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 4
... in Tripura due to naturally present arsenic, fuelling fears ... Health Engineering (PHE) department chief engineer Sunil Kumar Bhowmik ... that underground water contains arsenic of not less that ... for the tests were collected from Hrishyamukh and Santir ...
... genes to be produced from a single gene. By ... of proteins from a finite number of genes. A ... and the Howard Hughes Medical Institute, shows how the ... way that alternative splicing is controlled in the brain. ...
... who consume one portion of salmon per week are protected ... 43 percent, a study from Sweden has revealed. , ... Cancer has indicated the benefits of consuming omega-3 fatty acids ... cancer. Additionally, Fish is known to positively impact mood and ...
... indication of diabetes. Researchers from Harvard School of Public Health ... kill people much before they are even diagnosed with the ... nations. Their findings have shown that high blood sugar is ... results show that one in five deaths from heart disease ...
... According to a recent study, mice die early when exposed ... proposes working unusual // shifts and flying across time zones ... that older humans shorten their lives by flying across time ... might be a potential problems,' said study co-author Gene Block, ...
... H5N1 bird flu in its Fujian province as reported by a science ... Lin Friday refuted the report in the US Proceedings of the National ... its Fujian province had already spread to Malaysia, the Laos and Thailand, ... ,'In fact, there is no such thing as a new Fujian ...
Other Medicine News:Health News:Alternative Splicing - Molecular Cloning 2Health News:Alternative Splicing - Molecular Cloning 3Health News:Alternative Splicing - Molecular Cloning 4Health News:Jet Lag May Cause Health Problems: Study 2
... INC. (CBI) Prolactin ELISA kit is used ... human serum or plasma. Human prolactin (lactogenic ... with a molecular weight of approximately 23,000 ... a solid phase direct sandwich ELISA method. ...
... Prolactin ELISA Kit is enzyme immunoassay ... Human Prolactin (PRL) concentration in serum. ... quantitative determination of many protein hormones ... accurate, sensitive, reproducible, rapid and specific ...
... This Enzyme-Linked Immunosorbent Assay (ELISA) serves the ... from plasma, serum and,urine. In a 1 ... samples is bound to an,available excess of ... to the surface of the microtitre plates. ...
... The AxSYM BNP assay allows you ... the status of your heart due ... versus NT-ProBNP. The AxSYM BNP assay ... simple, walk-away resultson a platform that ...
Medicine Products: